The most common side effects include conjunctival hyperaemia (red eye), pain at the site where the medicine was applied, cornea verticillata (deposits in the cornea, the transparent layer in front of the eye that covers the pupil and iris), pruritus (itching of the eye), erythema (reddening) and discomfort in the eye, increased lacrimation (watery eyes), and conjunctival haemorrhage (bleeding in the surface layer of the eye).[2]
Netarsudil/latanoprost was approved for medical use in the United States in March 2019,[4] and in the European Union in January 2021.[2]
Medical usesedit
Netarsudil/latanoprost is indicated for the reduction of elevated intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension.[1][2]
Referencesedit
^ abcde"Rocklatan- netarsudil and latanoprost ophthalmic solution, 0.02%/0.005% solution/ drops". DailyMed. 10 March 2020. Retrieved 2 June 2020.
netarsudil, latanoprost, sold, under, brand, name, rocklatan, among, others, fixed, dose, combination, medication, treat, elevated, intraocular, pressure, people, with, open, angle, glaucoma, ocular, hypertension, contains, netarsudil, mesylate, latanoprost, a. Netarsudil latanoprost sold under the brand name Rocklatan among others is a fixed dose combination medication use to treat elevated intraocular pressure IOP in people with open angle glaucoma or ocular hypertension 1 2 It contains netarsudil mesylate and latanoprost 1 2 It is applied as eye drops to the eyes 1 2 Netarsudil latanoprostCombination ofNetarsudilRho kinase inhibitorLatanoprostProstaglandin F2a analogueClinical dataTrade namesRocklatan RoclandaAHFS Drugs comProfessional Drug FactsLicense dataUS DailyMed Netarsudil and latanoprostRoutes ofadministrationEye dropsATC codeS01EE51 WHO Legal statusLegal statusUS only 1 EU Rx only 2 3 IdentifiersKEGGD11558 The most common side effects include conjunctival hyperaemia red eye pain at the site where the medicine was applied cornea verticillata deposits in the cornea the transparent layer in front of the eye that covers the pupil and iris pruritus itching of the eye erythema reddening and discomfort in the eye increased lacrimation watery eyes and conjunctival haemorrhage bleeding in the surface layer of the eye 2 Netarsudil latanoprost was approved for medical use in the United States in March 2019 4 and in the European Union in January 2021 2 Medical uses editNetarsudil latanoprost is indicated for the reduction of elevated intraocular pressure IOP in adults with primary open angle glaucoma or ocular hypertension 1 2 References edit a b c d e Rocklatan netarsudil and latanoprost ophthalmic solution 0 02 0 005 solution drops DailyMed 10 March 2020 Retrieved 2 June 2020 a b c d e f g Roclanda EPAR European Medicines Agency EMA 9 November 2020 Retrieved 22 January 2021 Text was copied from this source which is c European Medicines Agency Reproduction is authorized provided the source is acknowledged Roclanda Product information Union Register of medicinal products Retrieved 3 March 2023 Drug Approval Package Rocklatan Ophthalmic Solution U S Food and Drug Administration FDA 20 November 2019 Retrieved 2 June 2020 Portal nbsp Medicine nbsp This pharmacology related article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Netarsudil latanoprost amp oldid 1213762520, wikipedia, wiki, book, books, library,
